CD38 and Miyoshi myopathy: The European Commission (EC) has granted conditional marketing authorization to talquetamab-tgvs (Talvey) monotherapy for the treatment of patients with r/r MM who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy [108].